Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03316794 Not yet recruiting - Cancer - Breast Clinical Trials

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Start date: November 13, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).

NCT ID: NCT03316586 Not yet recruiting - Breast Cancer Clinical Trials

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: - Cabozantinib (XL184) - Nivolumab

NCT ID: NCT03315364 Not yet recruiting - Clinical trials for Recurrent or Metastatic Breast Cancer

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Start date: November 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.

NCT ID: NCT03314870 Recruiting - Breast Cancer Clinical Trials

Development of a Response Signature to Neoadjuvant Chemotherapy for Breast Cancer

Start date: August 7, 2017
Phase: N/A
Study type: Interventional

Breast cancer is the most frequent cancer in women. It is often treated with neoadjuvant chemotherapy, administered before surgical resection. Unfortunately, many patients do not respond to this treatment, or only respond partially. Clinicians therefore need predictive biomarkers of treatment response. Thanks to an innovative technique, called CATS, this study aims at identifying blood and tissue biomarkers which are predictive of response to chemotherapy.

NCT ID: NCT03314805 Not yet recruiting - Clinical trials for Cancer-related Fatigue

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Start date: November 2017
Phase: Phase 2
Study type: Interventional

Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.

NCT ID: NCT03314688 Not yet recruiting - Breast Neoplasms Clinical Trials

Lifestyle, Exercise, and Nutrition Study Early After Diagnosis

Start date: November 2017
Phase: N/A
Study type: Interventional

The proposed study is a randomized trial evaluating the impact of a dietary and physical activity guidelines intervention vs. usual care on adherence to breast cancer treatments, body composition, and changes in biomarkers in 250 women newly diagnosed with breast cancer scheduled to receive neoadjuvant or adjuvant chemotherapy.

NCT ID: NCT03314168 Recruiting - Breast Cancer Clinical Trials

Adaptations to Breast Cancer and Exercise

Start date: October 7, 2017
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of different volumes of combined training on fatigue, neuromuscular variables, morphological, cardiorespiratory capacity, and quality of life, in breast cancer (BCa) women undergoing primary treatment. Two thirds will be the intervention group that will perform combined training, while the other third will be the control group that will have physiotherapy sessions.

NCT ID: NCT03313908 Not yet recruiting - Clinical trials for Breast Cancer Female

Radioguided Occult Lesion Localisation by Indocyanine Green

Start date: October 2017
Phase: N/A
Study type: Interventional

Breast cancer is the most common cancer in women. It is the main cause of cancer deaths among women. The incidence of non-palpable tumors is estimated at 60%. Their better prognosis and their small size encourage the investigators for finding methods simpler and more efficient to treat them by breast-conserving surgery with acceptable cosmetic results. The pre-operative detection of the tumor lesion is currently carried out by two methods: the radioactive seed localization and guidewire technique. Each has its disadvantages: the guidewire is uncomfortable for the patients (pain, hematomes..), whereas the radiocolloid requires a specialized and complex organization around this radioactive product. Recently, a novel method of using indocyanine green (ICG) fluorescence has been described in breast cancer and seems promising. In this study, investigators evaluate the feasibility and performance of indocyanine green fluorescence in non-palpable tumor detection in comparison with radioactive seed localization (ROLL) Secondary objectives are evaluate the feasibility of the location by the radiologist, feasibility of detection by the surgeon, study of the product and the probe.

NCT ID: NCT03312738 Recruiting - Clinical trials for Advanced Breast Cancer

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Start date: September 21, 2017
Phase: Phase 2
Study type: Interventional

This study aims at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- ABC after recurrence or progression on letrozole or anastrozole. The rationale of this study is based on the following: - Proven everolimus activity in breast cancer in combination with exemestane - Efficacy and manageable safety profile of everolimus in combination with exemestane in the Asian subpopulation of BOLERO-2

NCT ID: NCT03310957 Not yet recruiting - Breast Neoplasms Clinical Trials

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Start date: November 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This trial studies SGN-LIV1A in combination with pembrolizumab to find out what their side effects are and if they work for patients with triple-negative breast cancer that has spread to other parts of the body. Patients will be given both experimental drugs every 3 weeks.